NeuroPace, Inc. (NASDAQ:NPCE) Q1 2024 Earnings Call Transcript

And I expect to say a bit more about that going forward. But the punchline here would be that we’re investing in the business and we’re working to strike that balance between optimizing investments in critical longer term, as well as medium term product development and clinical data development initiatives, as well as investing in commercial execution of the business while maintaining good operating discipline. And so I think what you’re seeing from us here, if you look at the income statement, is some focused areas of investment in R&D, some expansion and investment in our commercial organization to continue to drive the top line, and real strong focus on expense control and operating discipline in all other areas.

Drew Ranieri: Got it. Thank you. And maybe just one on the procedure environment and diagnostic funnel environment in general, anything that you’re seeing in the first quarter, into the second quarter and anything that you would highlight. Thanks for taking the questions.

Joel Becker: Thank you. Drew, another good question. Just with regard to Q1 in particular, I would say that we’ve seen, and have seen here for the past few quarters, good, strong pipeline of patients and good consistency and robustness of what we’re seeing from individual centers and what we see from the pipeline more generally. So I think the pipeline looks good and consistent. Would you add anything to that, Rebecca?

Rebecca Kuhn: No, I think we’re pleased with what we see in the pipeline. We track patients and we place a lot of emphasis on that. And I think we’re pleased generally with seeing normalized EMU volumes and just where the patient pipeline is. So trends are positive.

Joel Becker: Thanks, Drew.

Operator: Thank you. There are no further questions at this time. Mr. Joel Becker, please proceed.

Joel Becker: Thank you, everyone, for listening to our Q1 2024 call today. As I mentioned earlier, here at NeuroPace, we’re excited about and focused on the opportunity to help close the treatment gap for drug resistant epilepsy patients by expanding access to RNS therapy. We’re excited about doing so. We look forward to executing on our growth strategy and to updating everyone our progress throughout 2024. Thank you.

Operator: Thank you. That concludes our conference for today. Thank you all for participating. You may all disconnect.